Cell-selective viral gene delivery vectors for the vasculature

Experimental Physiology

Volumn 90, Issue 1, 2005, Pages 27-31

  Baker, Andrew H ^a   Kritz, Angelika ^a   Work, Lorraine M ^a   Nicklin, Stuart A ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; PARVOVIRUS VECTOR; VASCULOTROPIN; VIRUS VECTOR;

CARDIOVASCULAR DISEASE; CONFERENCE PAPER; GENE THERAPY; HUMAN; NONHUMAN; SEROTYPE; VIRAL GENE DELIVERY SYSTEM;

EID: 12744272136     PISSN: 09580670     EISSN: None     Source Type: Journal    
DOI: 10.1113/expphysiol.2004.028126     Document Type: Conference Paper

References (43)

1. Arap W, Haedicke W, Bernascni M, Kain R, Rajotte D, Krajewski S et al. (2002a). Targeting the prostate for destruction through a vascular address. Proc Natl Acad Sci USA 99, 1527-1531.
2. Arap W, Kolonin M, Trepel M, Lahdenranta J, Cardo-Vila M, Giordano R et al. (2002b). Steps towards mapping the human vasculature by phage display. Nature Med 8, 121-127.
3. Back S & March KL (1998). Gene therapy for restenosis - getting near the heart of the matter. Circulation Res 82, 295-305.
4. Baker A (2004). Design of gene delivery vectors for cardiovascular gene therapy. Prog Biophysics Mol Biol 84, 279-299.
5. Baker A, Mehta D, George S & Angelini G (1997). Prevention of vein graft failure: potential applications for gene therapy. Cardiovascular Res 35, 442-450.
6. Chillon M, Bosch A, Zabner J, Law L, Armentano D et al. (1999). Group D adenoviruses infect primary central nervous system cells more efficiently than those from subgroup C. J Virol 73, 2537-2540.
7. Dishart K, Denby L, George S, Nicklin S, Yendluri S, Tuerk M et al. (2003). Third-generation lentivirus vectors efficiently transduce and phenotypically modify vascular cells: implications for gene therapy. J Mol Cell Cardiol 35, 739-748.
8. Dmitriev I, Krasnykh V, Miller CR, Wang MH, Kashentseva E, Mikheeva G et al. (1998). An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 72, 9706-9713.
9. French BA, Mazur W, Ali NM, Geske RS, Finnigan JP, Rodgers GP et al. (1994). Percutaneous transluminal in vivo gene transfer by recombinant adenovirus in normal porcine coronary arteries, atherosclerotic arteries, and two models of coronary restenosis. Circulation 90, 2402-2413.
10. Gaggar A, Shayakhmetov D & Lieber A (2003). CD46 is a cellular receptor for group B adenoviruses. Nature Med 9, 1-5.
11. Gao G-P, Alvira MR, Calcedo R, Johnston J & Wilson JM (2002). Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A 99, 11854-11859.
12. Gao G, Vandenberghe L, Alvira M, Lu Y, Calcedo R et al. (2004). Clades of adeno-associated viruses are widely disseminated in human tissues. J Virol 78, 6381-6388.
13. Girod A, Ried M, Wobus C, Lahm H, Leike K, Kleinschmidt J et al. (1999). Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nature Med 5, 1052-1056.
14. Gregorevic P, Blankinship MJ, Allen JM, Crawford RW, Meuse L, Miller DG et al. (2004). Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nature Med 10, 828-834.
15. Grines C, Watkins M, Helmer G, Penny W, Brinker J, Marmur JD et al. (2002). Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 105, 1291-1297.
16. Hacein-bey-abina S, Kalle C, Schmidt M, McCormack M, Wulffrast N, Leboulch P et al. (2003). LMO2-Associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302, 415-419.
17. Harari OA, Wickham TJ, Stocker CJ, Kovesdi I, Segal DM, Huehns TY et al. (1999). Targeting an adenoviral gene vector to cytokine-activated vascular endothelium via E-selectin. Gene Ther 6, 801-807.
18. Havenga MJE, Lemckert AAC, Grimbergen JM, Vogels R, Huisman LGM, Valerio D et al. (2001). Improved adenovirus vectors for infection of cardiovascular tissues. J Virol 75, 3335-3342.
19. Hedman M, Hartikainen J, Syvanne M, Stjernvall J, Hedman A, Kivela A et al. (2003). Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemai. Phase II results of the Kupoio Angiogenesis Trial (KAT). Circulation 107, 2677-2683.
20. Kohn D, Sadelain M & Glorioso J (2003). Occurrence of leukaemia following gene therapy of X-Linked SCID. Nature 3, 477-488.
21. Lehrman S (1999). Virus treatment questioned after gene therapy death. Nature 401, 517-518.
22. Lemarchand P, Jones M, Yamada I & Crystal RG (1993). In vivo gene transfer and expression in normal uninjured blood vessels using replication-deficient recombinant adenovirus vectors. Circulation Res 72, 1132-1138.
23. Melo LG, Agrawal R, Zhang L, Rezvani M, Mangi AA, Ehsan A et al. (2002). Gene therapy strategy for long-term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene. Circulation 105, 602-607.
24. Muller O, Kaul F, Weitzman M, Pasqualini R, Arap W et al. (2003). Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nature Biotechnol 21, 1040-1046.
25. Nabel EG, Plautz G & Nabel GJ (1991). Gene transfer into vascular cells. J Am College Cardiol 17, 189B-194B.
26. Nicklin S & Baker A (2002). Tropism-modified adenoviral and adeno-associated viral vectors for gene therapy. Current Gene Ther 2, 273-293.
27. Nicklin S, Buening H, Dishart K, De Alwis M, Girod A, Hacker U et al. (2001). Efficient and selective AAV2-mediated gene trasnfer directed to human vascular endothelial cells. Mol Ther 4, 174-181.
28. Nicklin S, White S, Nicol C, Seggern D & Baker A (2004). In vitro and in vivo characterisation of endothelial cell selective adenoviral vectors. J Gene Medicine 6, 300-308.
29. Nicklin S, White S, Watkins S, Hawkins R & Baker A (2000). Selective targeting of gene transfer to vascular endothelial cells by use of peptides isolated by phage display. Circulation 102, 231-237.
30. Nicol C, Graham D, Miller W, White S, Smith T, Nicklin S et al. (2004). Effect of adenovirus serotype 5 fiber and penton modifications on in vivo tropism in rats. Mol Ther 10, 343-353.
31. Pajusola K, Gruchala M, Joch H, Luscher T, Yla-Herttuala S & Bueler H (2002). Cell-type-specific characteristics modulate the transduction efficiency of adeno-associated virus type 2 and restrain infection of endothelial cells. J Virol 76, 11530-11540.
32. Pasqualini R, Koivunen E & Ruoslahti E (1995). A peptide isolated from phage display libraries is a structural and functional mimic of an RGD-binding site on integrins. J Cell Biol 130, 1189-1196.
33. Rajotte D, Arap W, Hagedorn M, Koivunen E, Pasqualini R & Ruoslahti E (1998). Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest 102, 430-437.
34. Reynolds P, Nicklin S, Kaliberova L, Boatman B, Grizzle W, Balyasnikova I et al. (2001). Combined transductional and transriptional targeting improves the specificty of transgene expression in vivo. Nature Biotechnol 19, 838-842.
35. Reynolds PN, Zinn KR, Gavrilyuk VD, Balyasnikova IV, Rogers BE, Buchsbaum DJ et al. (2000). A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo. Mol Ther 2, 562-578.
36. Richter M, Iwata A, Nyhuis J, Nitta Y, Miller A et al. (2000). Adeno-associated virus vector transduction of vascular smooth muscle cells in vivo. Physiol Genomics 2, 117-127.
37. Sarkar R, Tetreault R, Gao G, Wang L, Bell P, Chandler R et al. (2004). Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype. Gene Ther 103, 1253-1260.
38. Shi W & Bartlett JS (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol Ther 7, 515-525.
39. Trepel M, Grifman M, Weitzman MD & Pasqualini R (2000). Molecular adaptors for vascular-targeted adenoviral gene delivery. Human Gene Ther 11, 1971-1981.
40. White S, Nicklin S, Buening H, Brosnan MJ, Leike K, Papadakis E et al. (2004). Gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors. Circulation 109, 513-519.
41. Xia H, Anderson B, Mao Q & Davidson BL (2000). Recombinant human adenovirus: targeting to the human transferrin receptor improves gene transfer to brain microcapillary endothelium. J Virol 74, 11359-11366.
42. Yla-Herttuala S & Alitalo K (2003). Gene transfer as a tool to induce therapeutic vascular growth. Nature Med 9, 694-701.
43. Yla-Herttuala S & Martin J (2000). Cardiovascular gene therapy. Lancet 355, 213-217.